Page 1

Q3 First Patient Dosed in Optimize - 1 Phase II • On September 2 , the Company announced that it is exploring financing alternatives to support phase II studies for Mitazalimab , phase II preparations for ATOR - 1017 , as well as the development of other pipeline assets . " We continued to make great strides in the third quarter of 2021. The first patient was dosed in OPTIMIZE - 1 , our clinical Phase II study , that will assess the effect of mitazalimab in first line pancreatic cancer . We entered a collaboration with Finnish based Orion Corporation focusing on the discovery of novel immuno - oncology product candidates . With my first full quarter at the helm of this amazing company , I am even more confident in the potential value of our robust pipeline . " • On September 2 , the Company announced positive results from our collaboration with Scandion Oncology ( Sweden ) exploring the anti - tumor efficacy of the CD40 antibody mitazalimab in chemotherapy - resistant preclinical tumor models as an addition to chemotherapy ( FOLFIRINOX ) . • On September 30 , the Company announced first patient dosed in OPTIMIZE - 1 Phase II clinical trial evaluating mitazalimab in combination with mFOLFIRINOX for the treatment of Pancreatic Cancer . OPTIMIZE - 1 is an open - label , multicenter study that will enroll up to patients at clinical sites in Belgium and France . The company is expecting an interim safety readout in Q1 2022 and an interim efficacy readout in Q4 2022 . • On September 30th , Shanghai Henlius Biotech Inc. ( China ) reported that Alligator's partner program AC101 had entered into Phase II clinical trial . Søren Bregenholt CEO Alligator Bioscience AB ( publ ) Significant Events : July - September 2021 • On August 16 , New Senior Director of Communications and Investor Relations , Julie Silber , joined the Company , bringing a unique experience from Wall Street and 20+ years of investor relations , strategic communications , counsel , and executive financial leadership . Alligator Bioscience AB ( publ ) Interim report January - September 2021 • On August 18 , the Company entered into a research collaboration and license agreement with Orion Corporation , a global pharmaceutical company based in Finland , to discover and develop new immuno - oncology product candidates . DISCOVERY Neo - X - Prime ™ MacroGenics Neo - X - Prime ™ Inhouse PRECLINICAL 1 | Alligator Bioscience AB | Interim report January - September 2021 CLINICAL PHASE I ALG.APV - 527 ATOR - 1017 ALLIGATOR Events after the quarter : • On October 7 , the Board of Directors resolved , subject to approval by the Extraordinary General Meeting , to carry out a fully guaranteed rights issue of approximately SEK 257 million . • On October 7 , the Board of Directors called for an Extraordinary General Meeting to be held on November 8th , to seek approval of the Board of Directors ' resolution on rights issue of ordinary shares . Financial summary July - September 2021 • Net sales , SEK 3.3 million ( - ) Operating profit / loss , SEK -37.7 million ( -30.6 ) • Profit / loss for the period , SEK -37.2 million ( -30.8 ) Earnings per share before and after dilution , SEK -0.43 ( -0.43 ) • Cash flow for the period , SEK -30.4 million ( -32.7 ) • Cash and cash equivalents , SEK 79.3 million ( 137.0 ) ● bioscience January - September 2021 • Net sales , SEK 7.7 million ( 4.4 ) Operating profit / loss , SEK -104.7 million ( -110.2 ) • Profit / loss for the period , SEK - 104.9 million ( -108.8 ) Earnings per share before and after dilution , SEK -1.23 ( -1.52 ) • Cash flow for the period , SEK -24.0 million ( 42.6 ) • Cash and cash equivalents , SEK 79.3 million ( 137.0 ) CLINICAL PHASE II AC101 Mitazalimab ! The information was submitted for publication at 8:00 a.m. CET on October 21 , 2021. For contact details , see page 13 . Introduction